Anticancer therapy with novel tubulin-interacting drugs.
about
Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group StudyDiscovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.Asymmetric total synthesis of vindorosine, vindoline, and key vinblastine analoguesReview: tubulin function, action of antitubulin drugs, and new drug development.Synthesis and evaluation of a series of benzothiophene acrylonitrile analogs as anticancer agents.Total synthesis of the antimitotic marine macrolide (-)-leiodermatolide.The bioactive Taxol conformation on beta-tubulin: experimental evidence from highly active constrained analogs.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Total synthesis and evaluation of vinblastine analogues containing systematic deep-seated modifications in the vindoline subunit ring system: core redesign.[18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study.Protein-protein interactions as targets for small-molecule therapeutics in cancer.Protein electrophile-binding motifs: lysine-rich proteins are preferential targets of quinones.Multilevel induction of apoptosis by microtubule-interfering inhibitors 4β-S-aromatic heterocyclic podophyllum derivatives causing multi-fold mitochondrial depolarization and PKA signaling pathways in HeLa cellsTotal synthesis of vinblastine, vincristine, related natural products, and key structural analoguesTargeting microtubules by natural agents for cancer therapy.A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group studyMicrotubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.Optimising the delivery of tubulin targeting agents through antibody conjugation.Linobiflavonoid inhibits human lung adenocarcinoma A549 cells: effect on tubulin protein.Synthesis and biological evaluation of 2-arylamino-5- (3'-indolyl)-1,3,4-oxadiazoles as potent cytotoxic agents.Natural Compounds as Modulators of Cell Cycle Arrest: Application for Anticancer Chemotherapies.Identification of novel antitubulin agents by using a virtual screening approach based on a 7-point pharmacophore model of the tubulin colchi-site.A New Carbon Nanotube-Based Breast Cancer Drug Delivery System: Preparation and In Vitro Analysis Using Paclitaxel.Identification of gallic acid based glycoconjugates as a novel tubulin polymerization inhibitors.Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole.Scalarane-based metabolites isolated from the antimitotic extract of the marine sponge Hyrtios erectus.Microtubins: a novel class of small synthetic microtubule targeting drugs that inhibit cancer cell proliferation.Interactome Analysis of Microtubule-targeting Agents Reveals Cytotoxicity Bases in Normal Cells.Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines.
P2860
Q26781365-33439B71-905E-4DBE-9B3C-7D8E01F39D95Q30370631-2A1A059C-8B04-4F3F-9F7B-D822DFE48D4EQ31024172-2BE9EF18-B33E-4E1A-A3D7-CC6E7CA3EA04Q34152503-DD874570-5F71-40D8-AA21-5044F62F7AF3Q34425460-4886D4D2-A964-474A-A1F7-253B56196737Q34955360-2506B785-D190-453A-81D1-5AAA585C7349Q35842788-54A455FA-E677-4827-B53C-E4174A75DADAQ35970685-1B4DC8DC-A779-49EA-8FFB-33F1F19FD75DQ36061821-7113B053-DCC7-46B9-A0D8-C67B68CECCE1Q36561874-6312EB05-51CD-4E8B-B16F-BFD7F3AA4FC2Q36858129-D7B2C0C3-633B-4F7C-812A-F45EE04C3A27Q37114139-E60667BC-729F-411E-8874-080B894B9E37Q37196117-27644C42-89C5-4BA8-A6BC-9FE0691A8419Q37269285-BD63CDCA-6DCA-4D34-91A1-34508E397622Q37307990-4B0CF1D4-4948-4EEE-BE1F-AA803F1EC6B5Q37623838-1757A861-0A9B-4A42-95F6-6E90489C74CCQ37716223-48274B76-FBA1-4535-9160-FAC6EF3C74AAQ37722656-B73ADFF8-FA29-4FB0-836A-04CC416C0B0DQ38024991-E2D6D374-5F37-46AE-9183-B4F3525DE188Q39093037-98DF9513-BE35-472D-979A-5499861E8449Q39126991-1B8F2CDE-D115-41DC-88B1-870BB32E793AQ39214217-DD99FFE8-9F69-4EE5-B737-6822C14175E5Q39450385-54B5553D-A848-44C5-990A-52627DBBA440Q39833574-0362F671-93D6-4BB6-90EA-34275C3823BFQ40219453-07AD08BB-C409-43A2-A9A9-6A35A6F6BAE0Q42455386-49227290-65C1-49FF-AE2C-4D5FFEF08809Q44121057-D34347AF-F13A-4FC6-A341-53BFDD77496EQ47147267-FF83DC6E-CA50-4797-A293-6E754CA38178Q47288270-DC2473C4-D019-4D77-B66E-F98A73F41865Q49657822-D66A60BF-6980-4B4E-A382-DC23E9A0C8FB
P2860
Anticancer therapy with novel tubulin-interacting drugs.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Anticancer therapy with novel tubulin-interacting drugs.
@ast
Anticancer therapy with novel tubulin-interacting drugs.
@en
Anticancer therapy with novel tubulin-interacting drugs.
@nl
type
label
Anticancer therapy with novel tubulin-interacting drugs.
@ast
Anticancer therapy with novel tubulin-interacting drugs.
@en
Anticancer therapy with novel tubulin-interacting drugs.
@nl
prefLabel
Anticancer therapy with novel tubulin-interacting drugs.
@ast
Anticancer therapy with novel tubulin-interacting drugs.
@en
Anticancer therapy with novel tubulin-interacting drugs.
@nl
P2093
P356
P1476
Anticancer therapy with novel tubulin-interacting drugs.
@en
P2093
Kavallaris M
Verrills NM
P304
P356
10.1054/DRUP.2002.0230
P577
2001-12-01T00:00:00Z